Physician profile
Javier Murillo
NPI 1235293085
$11,532.14
in general payments reported to CMS, 2019-2025
24 companies · $1,333 in 2025
The $1,333 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $803 · 2020: $445 · 2021: $336 · 2022: $510 · 2023: $6,136 · 2024: $1,968 · 2025: $1,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,582 · Food and Beverage: $3,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,581.69 |
| Food and Beverage | $3,855.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,577.25 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,680.76 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $610.30 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Amgen INC. | $608.85 | 2023-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $485.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $427.90 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $196.69 | 2019-2022 | |
| Optinose US, INC. | $153.30 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $135.89 | 2019-2020 | |
| Pfizer INC. | $112.17 | 2019-2025 | |
| Dexcom, INC. | $86.70 | 2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Novartis Pharmaceuticals Corporation | $80.67 | 2024-2025 | |
| Abbott Laboratories | $65.72 | 2025 | Freestyle Libre 3 |
| Duchesnay USA Incorporated | $49.60 | 2019 | |
| Merz North America, INC. | $44.67 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $39.71 | 2019-2025 | Kristalose |
| Phadia US INC. | $34.60 | 2024 | Immunocap |
| Sanofi Pasteur INC. | $33.51 | 2020-2025 | |
| Strongbridge US INC. | $32.44 | 2020 | |
| Merck Sharp & Dohme LLC | $19.36 | 2022 | |
| Adamas Pharmaceuticals, INC. | $19.21 | 2020 | |
| Seqirus USA INC | $16.49 | 2025 | Fluad, Flucelvax |
| Becton, Dickinson and Company | $15.64 | 2023 | Bd Onclarity |
| Organon LLC | $5.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Murillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.